MTX 474
Alternative Names: MTX-474Latest Information Update: 08 Aug 2024
At a glance
- Originator Mediar Therapeutics
- Class Antifibrotics; Monoclonal antibodies
- Mechanism of Action Ephrin-B2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Fibrosis